This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will Endo's Troubles Continue to Dent Performance in 2017?
by Zacks Equity Research
2017 will continue to challenging for Endo Pharmaceuticals (ENDP) as the generics base business and the legacy branded pain franchise are expected to decline further.
AstraZeneca's Lung Cancer Drug Tagrisso Approved in China
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.
Merrimack (MACK) Starts Enrollment in Solid Tumors Study
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) announced that it has enrolled the first patient in a phase I study on MM-310 for solid tumors.
Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
by Zacks Equity Research
Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).
OvaScience, Inc. (OVAS) Looks Good: Stock Up 9.6% Higher
by Zacks Equity Research
OvaScience, Inc. (OVAS) shares rose almost 10% in the last trading session.
Enzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2%
by Zacks Equity Research
Enzo Biochem, Inc. (ENZ) shares rose above 5% in the last trading session.
AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher
by Zacks Equity Research
AveXis, Inc. (AVXS) shares rise above 15% in the last trading session.
Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3%
by Zacks Equity Research
Fortress Biotech, Inc. (FBIO) moved big last session, as its shares rose over 8% on the day.
Valeant (VRX) Shares up on ValueAct's 5.2% Stake Increase
by Zacks Equity Research
Shares of Valeant Pharmaceuticals (VRX) were up after investor ValueAct Capital management increased its stake in the company to 5.2%.
Implied Volatility Surging for Anthera (ANTH) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Anthera (ANTH) shares as it has huge implied volatility.
Shire's (SHPG) Cinryze Label Expanded for Pediatric Use
by Zacks Equity Research
Shire plc (SHPG) announced that the European Commission (EC) has approved a label extension for drug Cinryze for use in pediatrics.
Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA
by Zacks Equity Research
Endo International plc (ENDP) announced that the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees had consented that the benefits of reformulated Opana ER no longer outweigh its risks.
Inovio (INO) Q4 Loss Wider than Expected; Shares Decline
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) reported a loss of 36 cents for the fourth quarter of 2016.
Rexahn Pharmaceuticals (RNN) Jumps: Stock Moves Up 5.4%
by Zacks Equity Research
Rexahn Pharmaceuticals, Inc. (RNN) moved big last session, as its shares rose above 5% on the day.
VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y
by Zacks Equity Research
VIVUS Inc. (VVUS) reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period
New Strong Buy Stocks for March 8th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data
by Zacks Equity Research
Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.
Are Options Traders Betting on a Big Move in Anthera Pharmaceuticals (ANTH) Stock?
by Zacks Equity Research
Investors in Anthera Pharmaceuticals, Inc. (ANTH) need to pay close attention to the stock based on moves in the options market lately.